The OncLive Biosimilars condition center page is a comprehensive resource for clinical news and expert insights on currently available and investigational biosimilars for reference drugs such as trastuzumab, rituximab, bevacizumab, and more. This page features news articles, interviews in written and video format, and podcasts that focus on updates with biosimilars and ongoing research with these types of agents.
June 26th 2020
The Committee for Medicinal Products for Human Use has recommended approval of Aybintio, a bevacizumab (Avastin) biosimilar for the treatment of patients with the same types of cancer for which the reference product is indicated in the European Union.
June 22nd 2020
Praveen Ramakrishnan, MD, discusses the promise of biosimilars in hematology.
June 11th 2020
The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.
April 30th 2020
Sandra Cuellar, PharmD, BCOP, discusses the pharmacoeconomic benefits of biosimilars.
April 15th 2020
Trastuzumab-dttb (Ontruzant) is now officially available for clinical use in the United States.
March 6th 2020
The FDA has accepted a biologics license application for a proposed biosimilar for bevacizumab.
February 19th 2020
Ruth O’Regan, MD, shares her perspective on the use of biosimilars in breast cancer and their future in oncology.